Could Ebglyss challenge Dupixent in younger children? Almirall clears a crucial EMA filing hurdle
Almirall’s Ebglyss paediatric filing enters EMA review, opening a potential path into Europe’s childhood atopic dermatitis market.
Pharma & Biotech
Features & Analysis
How EBGLYSS shows the eczema market is moving from breakthrough launches to lifecycle strategy
Find out why fewer injections and longer disease control are becoming key battlegrounds in eczema biologics and dermatology care.
Pharma & Biotech
Why Lilly’s expanded Ebglyss label could reset dosing expectations in atopic dermatitis biologics
Ebglyss gains an every-eight-week FDA maintenance option, raising new questions for atopic dermatitis biologic competition.
Pharma & Biotech
Can Almirall turn dermatology momentum into a stronger long-term innovation engine?
Almirall’s dermatology engine is growing faster than group sales. The next test is whether biologics and pipeline bets can sustain momentum.